Navigation Links
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
Date:7/10/2012

LONDON, July 11, 2012 /PRNewswire/ -- Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1. The study demonstrated superiority of the dolutegravir-based regimen compared to the single tablet regimen Atripla®.  At 48 weeks, 88% of study participants on the dolutegravir regimen were virologically suppressed (<50 copies/mL) vs. 81% of participants on the single tablet regimen Atripla [difference and 95% CI; 7.4% (+2.5% to +12.3%); difference in the primary endpoint was statistically significant, p=0.003]. Differences in efficacy were primarily driven by a higher rate of discontinuation due to adverse events on the Atripla arm. The SINGLE study was designed to demonstrate non-inferiority of the dolutegravir-based regimen versus Atripla, and the primary analysis met this criterion.  Statistical superiority was concluded as part of a subsequent, pre-specified testing procedure.

SINGLE is an ongoing double blind, double dummy study designed to compare the efficacy and safety of two antiretroviral regimens: dolutegravir 50mg plus abacavir/lamivudine (Kivexa®/Epzicom®) versus Atripla® (tenofovir/emtricitabine/efavirenz). The primary endpoint was the proportion of study participants with undetectable HIV-1 RNA (<50c/mL) at 48 weeks; 414 treatment-naive study participants were randomised and exposed to the dolutegravir-based  regimen and 419 to the Atripla arm.  Overall, 2% of subjects on the dolutegravir-based regimen discontinued due to adverse events vs. 10% of those receiving the Atripla regimen. The most common drug related adverse events on Atripla were in the nervous system System Organ Class (reported by 41% of Atripla recipients, vs. 15% of participants receiving the dolutegravir-based regimen), while the most common drug relat
'/>"/>

SOURCE Shionogi-ViiV Healthcare LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. Netsmarts Focus on Innovation to Help Health and Human Service Providers Span the Spectrum of Care in the Healthcare 3.0 Environment
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Attendees Save Up To $800 on Global Healthcare Conferences in 2012 by Registering Through Global Information Inc.
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
7. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
8. Med Ad News Honors Healthcare Communication Agencies at 23rd Annual Manny Awards
9. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
10. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
11. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... , Oct. 16, 2014 The ... guidance on the application of single-use, or ... pharmaceutical and biopharmaceutical products with the publication ... Application of Single-Use Systems in Pharmaceutical ... described as single-use systems (SUS) or single-use ...
(Date:10/16/2014)... , Oct. 16, 2014 Curtis & ... under 3 weeks away from hosting their co-located ... Oral Drug Formulation Innovations Summit taking place ... San Diego, CA. November,s events ... organizations in streamlining the bioequivalence testing process, as well ...
(Date:10/16/2014)... PHILADELPHIA , Oct. 16, 2014 Ninety ... (ALL) who had relapsed multiple times or failed to ... an investigational personalized cellular therapy, CTL019, developed at the ... The results published today in The ... new data, which builds on preliminary findings presented at ...
Breaking Medicine Technology:PDA Offers Help in Applying Single-Use Systems to Bio/Pharma Operations 2Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 2Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 3Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 4Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 5Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied 6
... Health Corp. (Nasdaq: WBMD ) today announced the ... amount of 2.50% Convertible Notes due 2018 (including $50 million ... full of the initial purchaser,s over-allotment option).  The notes were ... under the Securities Act of 1933.   The ...
... NEW YORK, Jan. 11, 2011 Reportlinker.com ... is available in its catalogue: ... Price cuts set to negatively impact both ... http://www.reportlinker.com/p0360216/Spain-Pharmaceutical-Market-Overview – Price-cuts-set-to-negatively-impact-both-branded-and-generics-companies.html ...
Cached Medicine Technology:WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2Reportlinker Adds Spain Pharmaceutical Market Overview - Price cuts set to negatively impact both branded and generics companies 2
(Date:10/18/2014)... New York, New York (PRWEB) October 18, 2014 ... allege the IUD caused women to sustain serious injuries ... the uterus continue to mount in U.S. courts, Bernstein ... issued by the U.S. Judicial Panel on Multidistrict Litigation ... are now pending in the multidistrict litigation underway in ...
(Date:10/18/2014)... One major trend upcoming in this market is ... making efforts to encourage people to donate organs. The ... process more transparent and easy. , Analysts forecast the ... at a CAGR of 16.85 percent over the period ... drivers in the market is an increase in the ...
(Date:10/18/2014)... New York, New York (PRWEB) October 18, 2014 ... continue to mount in a mass tort litigation ... Pleas, Bernstein Liebhard LLP reports. According to court ... in the proceeding on behalf of Risperdal patients ... gynecomastia (male breast growth), due to their use ...
(Date:10/18/2014)... Oct. 18, 2014 (HealthDay News) -- Even determined dieters ... of healthy foods nearby, researchers say. Their new ... had metabolic syndrome (a combination of risk factors that ... And, all were told by their doctors to make ... The participants were involved in a clinical trial ...
(Date:10/18/2014)... is known to most people, ASP.NET hosting is a ... Cheap Hosting USA has compared many professional web ASP.NET ... JustHost are among the most reliable companies in the ... a good ASP.NET supplier. Actually, these companies have outperformed ... customer support. People can get the best web hosting ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 4Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 3Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 4Health News:Risperdal Lawsuits Mount, as Claims in Pennsylvania Litigation Near 900, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Mount, as Claims in Pennsylvania Litigation Near 900, Bernstein Liebhard LLP Reports 3Health News:Dieters May Be Thwarted by Absence of Healthy Foods 2
... News) -- Media multitasking -- the use of more than ... -- may have some positive effects, a new study suggests. ... which is especially common in young people and could include ... or social networking -- have received widespread publicity. But ...
... CINCINNATINew research at the University of Cincinnati (UC) ... a complex process that can provide cells with ... circumstances autophagy can protect tumor cells from chemotherapy, ... time in a hidden, dormant, metastatic state. ...
... , SUNDAY, April 15 (HealthDay News) -- A ... regions linked to fractures and osteoporosis. Variations in ... bone-weakening disease, the investigators reported in a new study published ... . The study authors added that their findings could ...
... appear to be rising, especially among high school students, ... is alarming and indicates more coaches and athletic trainers ... the game, according to researchers based at the University ... the number of football-related brain injuries with permanent disability ...
... Cancer is much more likely in the elderly than the ... disease and the often-toxic side effects of treatment. But ... The University of Texas Health Science Center at San Antonio shows ... younger patients can be used to help the elderly, with less ...
... , FRIDAY, April 13 (HealthDay News) -- In a new study ... of sun damage, middle schoolers showed evidence of levels of UV ... Not only can the technology spot who is most vulnerable ... noted, but it could also be used as a powerful deterrent ...
Cached Medicine News:Health News:Media Multitasking Might Have Mental Upside 2Health News:Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer 2Health News:Certain Genetic Regions May Be Tied to Osteoporosis 2Health News:Football-related catastrophic brain injuries on the rise 2Health News:Football-related catastrophic brain injuries on the rise 3Health News:Immunotherapy for elderly cancer patients finds new promise in drug combination 2Health News:Immunotherapy for elderly cancer patients finds new promise in drug combination 3Health News:Even Young Teens Show Signs of Sun Damage 2Health News:Even Young Teens Show Signs of Sun Damage 3Health News:Even Young Teens Show Signs of Sun Damage 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: